Biogen (BIIB) Notes Payables (2009 - 2025)

Biogen has reported Notes Payables for 12 years, with the latest figure at $1.7 billion in Q1 2025.

• On a quarterly basis, Notes Payables rose 599.64% year-over-year to $1.7 billion in Q1 2025; TTM through Mar 2025 was $1.7 billion, a 599.64% increase from a year earlier, with the FY2024 full-year figure at $1.7 billion, up 1065.73% from the prior year.
• Notes Payables was $1.7 billion for Q1 2025 at Biogen, roughly flat from $1.7 billion in the prior quarter.
• The five-year high for Notes Payables was $1.7 billion in Q1 2025, with the low at $150.0 million in Q4 2023.
• Average Notes Payables over 5 years is $1.0 billion, with a median of $999.3 million recorded in 2021.
• The largest YoY upside for Notes Payables was 1065.73% in 2024 against a maximum downside of 249.62% in 2024.
• Over 5 years, Notes Payables stood at $999.1 million in 2021, then climbed by 0.07% to $999.8 million in 2022, then tumbled by 85.0% to $150.0 million in 2023, then surged by 1065.73% to $1.7 billion in 2024, then rose by 0.03% to $1.7 billion in 2025.
• The last three Notes Payables figures came in at $1.7 billion (Q1 2025), $1.7 billion (Q4 2024), and $1.7 billion (Q3 2024), per Business Quant data.